• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Athira Pharma Inc (NQ: ATHA )

    0.4369 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,441
    Open 0.4369
    Bid (Size) 0.4380 (999)
    Ask (Size) 0.4500 (2)
    Prev. Close 0.4369
    Today's Range 0.4369 - 0.4369
    52wk Range 0.4128 - 4.298
    Shares Outstanding 38,054,583
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Robinhood To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
    From Athira Pharma, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -84.88%
    -84.88%
    1 Month
    -86.54%
    -86.54%
    3 Month
    -81.87%
    -81.87%
    6 Month
    -82.93%
    -82.93%
    1 Year
    -77.71%
    -77.71%

    More News

    Read More
    Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings
    Via Benzinga
    Exposures Fossil Fuels
    US Stocks Mixed; Trade Gap Widens In July
    Via Benzinga
    Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
    Via Benzinga
    Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
    From Athira Pharma, Inc.
    Via GlobeNewswire
    ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024
    Via InvestorPlace
    Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Participate in Upcoming June Conferences
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
    From Athira Pharma, Inc.
    Via GlobeNewswire
    ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024
    Via InvestorPlace
    Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Participate in Upcoming May Conferences
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
    From Athira Pharma, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.